Metabolic syndrome is characterized by dysregulated glucose metabolism and is a major risk factor for type 2 diabetes mellitus and cardiovascular disease. Although glucose-lowering therapies such as glucagon-like peptide-1 receptor (GLP-1R) agonists are effective, use may be limited by cost, administration route, side effects and tolerability. This in vitro study shows that a standardized, phospholipid-formulated bergamot extract (Vazguard™) stimulates GLP-1 receptor (GLP-1R) signaling pathways, offering a potential natural alternative for glucose modulation in metabolic syndrome.
Phospholipid-formulated bergamot extract (BP) exhibited a dose-dependent (0.31–5 mg/mL) increase in cAMP biosensor fluorescence, consistent with GLP-1R-associated signaling and a maximal response of approximately 60% relative to the positive control (GLP-1R agonist II). In contrast, BP showed no inhibitory effect on DPP4 activity and did not alter GLUT4-mediated glucose uptake under the experimental conditions tested.
Biomedicines. 2026, 14 May.
Metabolic syndrome is characterized by dysregulated glucose metabolism and is
We are pleased to announce that Innoprot has been recognised
Acetyl-l-carnitine (ALC) is synthesized in the brain, liver, and kidneys
Neural stem cell (NSC) proliferation and differentiation in the mammalian
Allergic conjunctivitis (AC) is the most common form of allergic
The hepatic content of amyloid beta (Aβ) decreases drastically in